Evidence map›Paper›PMID 31545896›Full record

ArticleLangmuir : the ACS journal of surfaces and colloids2019

A Robust and General Approach to Quantitatively Conjugate Enzymes to Plasmonic Nanoparticles.

Yuyang Wang, Karsten van Asdonk, Peter Zijlstra

Abstract read
In one paragraph

Article in Langmuir : the ACS journal of surfaces and colloids, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yuyang WangDepartment of Applied Physics , Eindhoven University of Technology , 5600 MB , Eindhoven , The Netherlands.ORCID 0000-0001-5175-8389
Karsten van AsdonkDepartment of Biomedical Engineering , Eindhoven University of Technology , 5600 MB , Eindhoven , The Netherlands.
Peter ZijlstraDepartment of Applied Physics , Eindhoven University of Technology , 5600 MB , Eindhoven , The Netherlands.ORCID 0000-0001-9804-2265

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bioconjugates of plasmonic nanoparticles have received considerable attention due to their potential biomedical applications. Successful bioconjugation requires control over the number and activity of the conjugated proteins and the colloidal stability of the particles. In practice, this requires reoptimization of the conjugation protocol for each combination of protein and nanoparticle. Here, we report a robust and general protocol that allows for the conjugation of a range of proteins to different types of nanoparticles using very short polyethylene-glycol(PEG) linkers, while simultaneously preserving protein activity and colloidal stability. The use of short linkers ensures that the protein is located close to the particle surface, where the refractive index sensitivity and near-field enhancement are maximal. We demonstrate that the use of a Tween20 containing stabilizing buffer is critical in maintaining colloidal stability and protein function throughout the protocol. We obtain quantitative control over the average number of enzymes per particle by either varying the number of functional groups on the particle or the enzyme concentration during incubation. This new route of preparing quantitative protein-nanoparticle bioconjugates paves the way to develop rational and quantitative strategies to functionalize nanoparticles for applications in sensing, medical diagnostics, and drug delivery.

Indexed as

ColloidsEnzymes, ImmobilizedNanoparticlesPolyethylene GlycolsColloidsEnzymes, ImmobilizedPolyethylene Glycols

Identifiers

PMID31545896
PMCPMC6798157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.